Health Economics›Kaposi sarcoma›All lines of therapy

All lines of therapy

Kaposi sarcoma · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	~6.7 mo	~19.6 mo	~2	~R 38 164 PFS proxy · indirect	10
Pegylated liposomal doxorubicin monotherapy Variant #02	—	R 8 000	28d	~4.2 mo	~13.5 mo	~6	~R 48 000 PFS proxy · indirect	24
Pomalidomide monotherapy Variant #01	—	R 4 782	28d	~2.7 mo	—	~2	~R 9 564 PFS proxy · indirect	1
ABV (Vinblastine) Variant #01 Partial	—	R 1 895	28d	—	—	~2	~R 3 790 indirect	—
Etoposide monotherapy Variant #01	—	R 1 231	28d	—	—	~6	~R 7 386 indirect	—
Paclitaxel monotherapy Variant #02	—	R 734	28d	~4.8 mo	~12.0 mo	~7	~R 5 141 PFS proxy · indirect	85
ABV (Vincristine) Variant #01 Partial	—	R 389	14d	—	—	~6	~R 2 332 indirect	—
Bleomycin and Vincristine (BO) Variant #01 Partial	—	R 327	14d	—	—	~1	~R 327 indirect	—
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	~13.2 mo	—	~6	—	2
Placebo Partial	—	—	—	~1.3 mo	~7.6 mo	—	—	11
Alitretinoin monotherapy Variant #01 Partial	—	—	84d	—	—	~1	—	—
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	~5.4 mo	~17.5 mo	~2	—	10
Daunorubicin liposomal monotherapy Variant #01 Partial	—	—	14d	—	—	~2	—	—

13 of 13 regimens shown